Literature DB >> 3516187

Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy.

P G Agostoni, N De Cesare, E Doria, A Polese, G Tamborini, M D Guazzi.   

Abstract

Nifedipine and captopril are potent vasodilators and may be expected to help left ventricular failure by reducing afterload. Nifedipine (20 mg three times a day) and captopril (50 mg three times a day) were added to an optimal regimen of digitalis and diuretics in a double blind crossover trial in 18 cases of dilated cardiomyopathy. New York Heart Association functional class rating symptoms and exercise tolerance times improved on captopril but not on nifedipine. The reduction in pulmonary capillary wedge pressure and the increase of cardiac output on captopril indicated that the augmented functional capacity may have resulted in part from an improved performance of the left ventricle. Although there were comparable decreases in systemic vascular resistance and presumably in impedence to ejection by the left ventricle on both drugs, the dimensions of the ventricular cavity were found to be reduced by captopril and augmented by nifedipine, and only captopril reduced the afterload (wall stress). In addition, the force-length relation (between left ventricular end systolic stress and end systolic diameter) was shifted to the left of baseline by captopril and to the right by nifedipine, suggesting that muscle contractility was reduced by nifedipine and not by captopril. These results suggest that nifedipine and captopril have different effects on afterload and contractility and these may account for the different effects of these drugs on the performance of the heart and clinical responses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516187      PMCID: PMC1236744          DOI: 10.1136/hrt.55.4.391

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  19 in total

1.  Instantaneous force-velocity-length relations: experimental findings and clinical correlates.

Authors:  K T Weber; J S Janicki
Journal:  Am J Cardiol       Date:  1977-11       Impact factor: 2.778

Review 2.  Vasodilator therapy of cardiac failure: (first of two parts).

Authors:  J N Cohn; J A Franciosa
Journal:  N Engl J Med       Date:  1977-07-07       Impact factor: 91.245

3.  Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure.

Authors:  T B Levine; J A Franciosa; J N Cohn
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

4.  Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor.

Authors:  R Ader; K Chatterjee; T Ports; B Brundage; B Hiramatsu; W Parmley
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

5.  Wall stress and patterns of hypertrophy in the human left ventricle.

Authors:  W Grossman; D Jones; L P McLaurin
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

6.  Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme.

Authors:  R Davis; H S Ribner; E Keung; E H Sonnenblick; T H LeJemtel
Journal:  N Engl J Med       Date:  1979-07-19       Impact factor: 91.245

7.  Disparate unloading efficacy of the calcium channel blockers, verapamil and nifedipine, on the failing hypertensive left ventricle.

Authors:  M D Guazzi; C Cipolla; P Della Bella; F Fabbiocchi; P Montorsi; P Sganzerla
Journal:  Am Heart J       Date:  1984-07       Impact factor: 4.749

8.  Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension.

Authors:  M D Guazzi; N De Cesare; C Galli; A Salvioni; C Tramontana; G Tamborini; A Bartorelli
Journal:  Circulation       Date:  1984-08       Impact factor: 29.690

9.  Clinical use of a calcium antagonistic agent (nifedipine) in acute pulmonary edema.

Authors:  A Polese; C Fiorentini; M T Olivari; M D Guazzi
Journal:  Am J Med       Date:  1979-05       Impact factor: 4.965

10.  Hemodynamic effects of nifedipine in congestive heart failure.

Authors:  S Matsumoto; T Ito; T Sada; M Takahashi; K M Su; A Ueda; F Okabe; M Sato; I Sekine; Y Ito
Journal:  Am J Cardiol       Date:  1980-09       Impact factor: 2.778

View more
  14 in total

1.  Radionuclide monitoring of left ventricular function after sublingual nifedipine administration at rest and during moderate physical activity.

Authors:  A Ferro; M Salvatore; A Cuocolo
Journal:  J Nucl Cardiol       Date:  2001 Nov-Dec       Impact factor: 5.952

Review 2.  Vascular tone in heart failure: the neuroendocrine-therapeutic interface.

Authors:  J G Cleland; C M Oakley
Journal:  Br Heart J       Date:  1991-10

Review 3.  Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks.

Authors:  U Ravens; M Wehr
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 4.  Calcium-channel blockers and anaesthesia.

Authors:  P G Durand; J J Lehot; P Foëx
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

Review 5.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 6.  Pathophysiologic arguments for vasodilators in cardiac failure.

Authors:  A Vogt; K L Neuhaus; H Kreuzer
Journal:  Cardiovasc Drugs Ther       Date:  1988-12       Impact factor: 3.727

Review 7.  The role of vasodilator therapy in the treatment of severe chronic heart failure.

Authors:  M Packer
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure.

Authors:  L Dei Cas; M Metra; R Ferrari; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

9.  Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure.

Authors:  T Takahashi; P D Allen; R V Lacro; A R Marks; A R Dennis; F J Schoen; W Grossman; J D Marsh; S Izumo
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

Review 10.  The ever expanding spectrum of ischemic left ventricular dysfunction.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1994-05       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.